ChronoScale Corporation

Revenue was $2.1 million in Q2 2025 versus $5 million in Q2 2024. Gross profit was $800,000, with gross margin of approximately 40%, versus $2.6 million and 53% in the prior-year quarter. Operating expenses were $4.8 million, down 4% from $5 million a year ago. Net loss applicable to common stockholders was $2.7 million, or $1.24 per basic and diluted share, versus a net loss of $2.4 million, or $1.99 per basic and diluted share, in Q2 2024. Cash and restricted cash were $5.2 million at June 30, 2025. Management did not give formal quarterly or full-year financial guidance, but said it believes a significant portion of deferred Enterprise Health sales can close before year-end, including a North American IDN order in the $1 million range that it expects in Q3, and the combined deferred Enterprise Health deals totaled about $1.4 million. It also said Personal Health was about 10% of revenue in 2024 and is expected to be closer to 25% of total revenue in 2025, with the possibility that Personal Health could begin overtaking Enterprise Health around 2027.

Scott Davis framed Q2 as an “abnormally weak” quarter driven mostly by timing delays, not a change in underlying demand. He emphasized that two deferred Enterprise Health deals remain live, that the company is working to improve reimbursement and financing pathways, and that Personal Health is scaling through PRIA, NSM, Bionic P&O, and additional O&P and VA/workers’ compensation efforts. He was notably optimistic about the AI initiative, saying Ekso’s data set and NVIDIA Connect access could help create a proprietary foundation model for human motion and rehabilitation.

Jerome Wong focused on the reported numbers and the drivers behind them: revenue of $2.1 million, gross profit of $800,000, gross margin of 40%, operating expenses of $4.8 million, and a $2.7 million net loss. He said the revenue decline was primarily caused by short-term delays in closing multi-device Enterprise Health sales, partially offset by higher Ekso Indego Personal sales, while the gross margin compression reflected fixed costs against lower Enterprise Health volume, lower-margin distribution sales, and higher shipping costs. He also disclosed cash and restricted cash of $5.2 million at quarter-end.

Analysts pressed on how much Enterprise Health revenue was deferred and when it might return; management said the delayed business consisted of two multiunit sales, one international order delayed by regulatory issues and one North American IDN order in the $1 million range, totaling about $1.4 million, with the North American deal expected in Q3 and the international deal expected within 2025. Questions also focused on when Personal Health could overtake Enterprise Health; Scott Davis said Personal Health could reach about 25% of revenue in 2025 and begin to overtake Enterprise Health around 2027. On reimbursement and commercialization, management said claims are working through the ALJ process with some approvals and remands, and that PRIA and distribution partners are helping build a more repeatable claims and patient-selection process.